Work

MDS-773 Development of Oral Azacitidine With Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including Chronic Myelomonocytic Leukemia (CMML) by Targeting Pharmacokinetic AUC Equivalence vs Subcutaneous Azacitidine

Year: 2024

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(24)01383-1

Authors: Guillermo Garcia-Manero, James McCloskey, Bart L. Scott, Elizabeth A. Griffiths, Bonnie Kiner-Strachan, Gail J. Roboz, Janelle Meyer, Winny Chan, Yuri Sano, Aram Oganesian, Harold K. Keer, Michael R. Savona

Institutions: The University of Texas MD Anderson Cancer Center, Hackensack University Medical Center, Fred Hutch Cancer Center, Roswell Park Comprehensive Cancer Center, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Taiho Oncology (United States), Vanderbilt University, Vanderbilt-Ingram Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4401875777

Cites:

Cited by:

Related to: 10